Compounds > fenofibrate
Page last updated: 2024-10-27

fenofibrate and HIV Coinfection

fenofibrate has been researched along with HIV Coinfection in 16 studies

Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE

Research Excerpts

ExcerptRelevanceReference
"Fish oil was safe when administered alone or combined with fenofibrate and significantly reduced TG levels in HIV-infected subjects with hypertriglyceridemia."9.13Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. ( Aberg, JA; Acosta, EP; Benson, CA; Charles, S; Connick, E; Fichtenbaum, CJ; Gerber, JG; Hogg, E; Kitch, DW; Kojic, EM; Wohl, D; Zackin, RA, 2008)
"The authors review current literature on the use of fenofibrate and related derivatives in HIV-infected people with dyslipidemia using antiretroviral therapy."8.86Fenofibrate in the treatment of dyslipidemia associated with HIV infection. ( Fichtenbaum, CJ; Samineni, D, 2010)
"We present what we believe to be the first case in the literature of rhabdomyolysis-induced renal failure caused by a probable drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) and pravastatin/fenofibrate."7.81A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report. ( Florence, E; Kenyon, C; Leys, J; Suttels, V; Van den Ende, J; Vekemans, M; Vlieghe, E, 2015)
"Fish oil was safe when administered alone or combined with fenofibrate and significantly reduced TG levels in HIV-infected subjects with hypertriglyceridemia."5.13Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. ( Aberg, JA; Acosta, EP; Benson, CA; Charles, S; Connick, E; Fichtenbaum, CJ; Gerber, JG; Hogg, E; Kitch, DW; Kojic, EM; Wohl, D; Zackin, RA, 2008)
"Fenofibrate therapy improves the atherogenic lipid profile in HIV-positive adults with hypertriglyceridemia."5.11Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. ( Badiou, S; Baillat, V; Cristol, JP; Dupuy, AM; Merle De Boever, C; Reynes, J, 2004)
"The authors review current literature on the use of fenofibrate and related derivatives in HIV-infected people with dyslipidemia using antiretroviral therapy."4.86Fenofibrate in the treatment of dyslipidemia associated with HIV infection. ( Fichtenbaum, CJ; Samineni, D, 2010)
"We present what we believe to be the first case in the literature of rhabdomyolysis-induced renal failure caused by a probable drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) and pravastatin/fenofibrate."3.81A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report. ( Florence, E; Kenyon, C; Leys, J; Suttels, V; Van den Ende, J; Vekemans, M; Vlieghe, E, 2015)
" There were few adverse events and no rhabdomyolysis reported."2.71A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. ( Aberg, JA; Alston, BL; Brobst, SW; Evans, SR; Fichtenbaum, CJ; Glesby, MJ; Henry, WK; Owens, SI; Torriani, FJ; Yang, Y; Zackin, RA, 2005)
"Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI)."2.70Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. ( Caramelli, B; de Bernoche, CY; Monachini, MC; Santos, RD; Sartori, AM; Sposito, AC; Strabelli, T; Uip, D, 2001)
"Treatment with fenofibrate (200 mg qd), however, was followed by a significant reduction of triglyceride and cholesterol concentrations to 12 mmol/L (1050 mg/dL) and 10 mmol/L (387 mg/dL)."1.32[HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia]. ( Battegay, M; Hirsch, HH, 2003)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's8 (50.00)29.6817
2010's7 (43.75)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Muñoz, MA1
Liu, W1
Delaney, JA1
Brown, E1
Mugavero, MJ1
Mathews, WC1
Napravnik, S1
Willig, JH1
Eron, JJ1
Hunt, PW1
Kahn, JO1
Saag, MS1
Kitahata, MM1
Crane, HM1
Grandi, AM1
Nicolini, E1
Rizzi, L1
Caputo, S1
Annoni, F1
Cremona, AM1
Marchesi, C1
Guasti, L1
Maresca, AM1
Grossi, P1
Dubé, MP1
Komarow, L1
Fichtenbaum, CJ4
Cadden, JJ1
Overton, ET1
Hodis, HN1
Currier, JS1
Stein, JH1
Suttels, V1
Florence, E1
Leys, J1
Vekemans, M1
Van den Ende, J1
Vlieghe, E1
Kenyon, C1
Samineni, D1
Grinspoon, S1
Fitch, K1
Wooten, JS1
Nambi, P1
Gillard, BK1
Pownall, HJ1
Coraza, I1
Scott, LW1
Nambi, V1
Ballantyne, CM1
Balasubramanyam, A1
Palacios, R1
Santos, J1
González, M1
Ruiz, J1
Valdivielso, P1
Márquez, M1
González-Santos, P1
Hirsch, HH1
Battegay, M1
de Luis, DA2
Bachiller, P1
Aller, R2
Eiros Bouza, J1
Izaola, O1
Badiou, S1
Merle De Boever, C1
Dupuy, AM1
Baillat, V1
Cristol, JP1
Reynes, J1
Aberg, JA2
Zackin, RA2
Brobst, SW1
Evans, SR1
Alston, BL1
Henry, WK1
Glesby, MJ1
Torriani, FJ1
Yang, Y1
Owens, SI1
Gerber, JG1
Kitch, DW1
Charles, S1
Hogg, E1
Acosta, EP1
Connick, E1
Wohl, D1
Kojic, EM1
Benson, CA1
Rachiller, P1
Ignacio Tortosa, J1
Bonnet, E1
Ruidavets, JB1
Tuech, J1
Ferrières, J1
Collet, X1
Fauvel, J1
Massip, P1
Perret, B1
Caramelli, B1
de Bernoche, CY1
Sartori, AM1
Sposito, AC1
Santos, RD1
Monachini, MC1
Strabelli, T1
Uip, D1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate[NCT01426438]Phase 299 participants (Actual)Interventional2011-11-30Completed
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376]221 participants (Actual)Interventional2004-01-31Completed
A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities[NCT00006412]Phase 3630 participants InterventionalCompleted
Antiretroviral Effect of Lovastatin on HIV-1-infected Individuals Without Highly Active Antiretroviral Therapy (HAART): A Phase-II Randomized Clinical Trial (RCT)[NCT00721305]Phase 2112 participants (Actual)Interventional2008-08-31Completed
A Phase II Trial of the Effect of Combination Therapy With Fish Oil Supplement and Fenofibrate on Triglyceride (TG) Levels in Subjects on Highly Active Antiretroviral Therapy (HAART) Who Are Not Responding to Either Fish Oil or Fenofibrate Alone[NCT00076518]Phase 2100 participants InterventionalCompleted
Role of Omega-3 Fish Oil Fatty Acids on Depression Among HIV-seropositive Pregnant Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial[NCT01614249]216 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Absolute Change in Relative FMD (%)

The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Intervention% FMD (Median)
Arm A: Extended-release Niacin With Aspirin0.60
Arm B: Fenofibrate0.50

Change in C-reactive Protein (CRP)

Change in C-reactive protein from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionug/ml (Median)
Arm A: Extended-release Niacin With Aspirin-0.6
Arm B: Fenofibrate0.7

Change in Cholesterol

Absolute change in total cholesterol from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-9
Arm B: Fenofibrate-2

Change in D-Dimer

Change in D-Dimer from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionug/ml (Median)
Arm A: Extended-release Niacin With Aspirin0.06
Arm B: Fenofibrate0.06

Change in HDL Particles

Change in total HDL particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin-1.7
Arm B: Fenofibrate4.3

Change in HOMA-IR

Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR (NCT01426438)
Timeframe: 0 and 24 weeks

InterventionHOMA IR Score (Median)
Arm A: Extended-release Niacin With Aspirin1.3
Arm B: Fenofibrate0.3

Change in IL-6

Change in IL-6 from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionpg/ml (Median)
Arm A: Extended-release Niacin With Aspirin0.1
Arm B: Fenofibrate0.2

Change in Large HDL Particles

Change in Large HDL Particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin0.9
Arm B: Fenofibrate-0.3

Change in LDL Cholesterol

Change in LDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-1
Arm B: Fenofibrate7

Change in Non-HDL Cholesterol

Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-17
Arm B: Fenofibrate-4

Change in Small LDL Particles

Change in Small LDL particles from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin-176
Arm B: Fenofibrate-119

Change in Triglycerides

Change in Triglycerides (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-65
Arm B: Fenofibrate-54

Men: Change in HDL Cholesterol

Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin3
Arm B: Fenofibrate6.5

Women: Change in HDL Cholesterol

Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin16
Arm B: Fenofibrate8

HDL-C

HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care37.1
Group 2 - Diet/Exercise Only38.7
Group 3 - Diet/Exercise + Fenofibrate40.7
Group 4 - Diet/Exercise + Niacin41.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin44.8

Non-HDL-C

non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care162.2
Group 2 - Diet/Exercise Only165.4
Group 3 - Diet/Exercise + Fenofibrate145.8
Group 4 - Diet/Exercise + Niacin154
Group 5 - Diet/Exercise + Fenofibrate + Niacin137.1

Total Cholesterol

Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care195.6
Group 2 - Diet/Exercise Only200.1
Group 3 - Diet/Exercise + Fenofibrate184
Group 4 - Diet/Exercise + Niacin190.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin178.4

Total Cholesterol : HDL-C Ratio

Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionratio (Mean)
Group 1 - Usual Care5.2
Group 2 - Diet/Exercise Only5.1
Group 3 - Diet/Exercise + Fenofibrate4.5
Group 4 - Diet/Exercise + Niacin4.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin4

Triglycerides

Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care199
Group 2 - Diet/Exercise Only216.9
Group 3 - Diet/Exercise + Fenofibrate155.1
Group 4 - Diet/Exercise + Niacin177.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin135.6

Body Composition

"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionkg (Mean)
Body cell massFat mass
Group 1 - Usual Care59.636.8
Group 2 - Diet/Exercise67.337.5
Group 3 - Diet/Exercise + Fenofibrate66.635.8
Group 4 - Diet/Exercise + Niacin67.137.7
Group 5 - Diet/Exercise + Fenofibrate + Niacin68.236.2

Insulin Sensitivity

Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionmicrograms/ml (Mean)
Fasting insulinHOMA-IRInsulin sensitvity indexAdiponectin
Group 1 - Usual Care8.71.923.547.12
Group 2 - Diet/Exercise Only6.71.384.956.04
Group 3 - Diet/Exercise + Fenofibrate9.52.023.815.24
Group 4 - Diet/Exercise + Niacin11.92.762.8811.01
Group 5 - Diet/Exercise + Fenofibrate + Niacin10.32.382.3810.34

Change in BDI-II Depressive Symptom Scores

Depressive symptoms were assessed by Beck Depression Inventory Second Edition (BDI-II) Scoring scale at Baseline and end of study during the 8- week study period. The BDI-II Scale is a 21-item scoring tool which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represent a depressive symptom. The symptoms are each scored on a 4-point Likert scale of 0 to 3 (0=symptom is absent; 3=symptom is severe).Scores for each symptom are added up to obtain the total scores for all 21 items, which are interpreted as follows: Scores of 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression and 29-63: severe depression. The change in BDI-II scores were computed from post-intervention scores at week 8 and baseline BDI-II scores at week 0. (NCT01614249)
Timeframe: 8 weeks

Interventionscores on BDI-II scale (Mean)
Soybean Oil Soft Gels Control Group-13.9
Fish Oil Omega-3 EPA-rich Soft Gels Experimental Group-13.3

Reviews

1 review available for fenofibrate and HIV Coinfection

ArticleYear
Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:8

    Topics: Anti-HIV Agents; Cholesterol, HDL; Coronary Disease; Dyslipidemias; Fenofibrate; HIV Infections; Hum

2010

Trials

8 trials available for fenofibrate and HIV Coinfection

ArticleYear
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
    Journal of the International AIDS Society, 2014, Volume: 17

    Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslip

2014
Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Sep-01, Volume: 61, Issue:5

    Topics: Adult; Brachial Artery; C-Reactive Protein; Cholesterol, HDL; Delayed-Action Preparations; Dyslipide

2015
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
    Medicine and science in sports and exercise, 2013, Volume: 45, Issue:6

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Antiretroviral Therapy, Highly Active;

2013
Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2002, Oct-01, Volume: 31, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Fenofibrate; HIV Infect

2002
Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
    Atherosclerosis, 2004, Volume: 172, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins B; Apolipop

2004
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:9

    Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypo

2005
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:9

    Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypo

2005
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:9

    Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypo

2005
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:9

    Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypo

2005
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
    Journal of acquired immune deficiency syndromes (1999), 2008, Apr-01, Volume: 47, Issue:4

    Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fish Oils

2008
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
    Journal of acquired immune deficiency syndromes (1999), 2008, Apr-01, Volume: 47, Issue:4

    Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fish Oils

2008
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
    Journal of acquired immune deficiency syndromes (1999), 2008, Apr-01, Volume: 47, Issue:4

    Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fish Oils

2008
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
    Journal of acquired immune deficiency syndromes (1999), 2008, Apr-01, Volume: 47, Issue:4

    Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fish Oils

2008
Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2001, Volume: 5, Issue:6

    Topics: Adult; Aged; CD4 Lymphocyte Count; Cholesterol; Female; Fenofibrate; HIV Infections; HIV Protease In

2001

Other Studies

7 other studies available for fenofibrate and HIV Coinfection

ArticleYear
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Ef

2013
A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report.
    Journal of medical case reports, 2015, Sep-08, Volume: 9

    Topics: Acute Kidney Injury; Aged; Anti-HIV Agents; Anticholesteremic Agents; Drug Interactions; Elvitegravi

2015
Therapy: HIV-associated dyslipidemia: the heart positive study.
    Nature reviews. Endocrinology, 2011, Jun-21, Volume: 7, Issue:8

    Topics: Drug Therapy, Combination; Dyslipidemias; Exercise Therapy; Fenofibrate; Heart Diseases; HIV Infecti

2011
[HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
    Deutsche medizinische Wochenschrift (1946), 2003, May-09, Volume: 128, Issue:19

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocy

2003
Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
    Nutrition (Burbank, Los Angeles County, Calif.), 2003, Volume: 19, Issue:10

    Topics: Adult; Anticholesteremic Agents; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; HIV-1

2003
[Reversibility of severe hyperlipemia secondary to indinavir with micronized phenofibrate].
    Medicina clinica, 1999, Nov-27, Volume: 113, Issue:18

    Topics: Administration, Oral; Adult; Fenofibrate; Hemophilia A; HIV Infections; HIV Protease Inhibitors; Hum

1999
Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy.
    The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:1

    Topics: Adult; Anti-HIV Agents; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Apolipoproteins E;

2001